Protein tyrosine kinase 7 (PTK7) is a pseudo tyrosine kinase overexpressed in many cancer types such as ovarian, triple-negative breast cancer (TNBC), non-small-cell lung cancer, small-cell lung ...

DAY301 targets PTK7, a highly-conserved, catalytically inactive transmembrane protein that is overexpressed in multiple adult cancers, including esophageal, ovarian, lung, and endometrial cancer ...

Day One has inked a $1.2 billion biobucks deal with MabCare Therapeutics for rights to an ADC taking aim at solid tumors in both adults and kids.

ProfoundBio CEO Baiteng Zhao. (ProfoundBio Photo) ProfoundBio raised $112 million to support development of its pipeline of antibody-drug conjugates ...

J., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA. Cancer J. Clin. 2021, 71, 209–249 About Agilent Technologies ...

This is the first immunohistochemistry companion diagnostic test to be made widely available in Europe to aid in identifying epithelial ovarian cancer patients who may be eligible for targeted ...

Genmab is slated to acquire antibody- drug-conjugate (ADC) developer ProfoundBio for $1.8 billion. The Danish pharma firm will gain three clinical-stage drug candidates: rinatabart sesutecan, an ...

BioWorld - Saturday, February 22, 2025 Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review See today's BioWorld Science Home » New PTK7-directed antibody effective in ...